tbuckley/cabot-search huggingface dataset:
Antifibrinolytic therapy in the management of the kasabach merritt syndrome
Authors: Thomas L. Ortel, James J. Onorato, Camille L. Bedrosian, Russel E. Kaufman
Journal: American Journal of Hematology (1988)

Abstract The Kasabach Merritt syndrome consists of thrombocytopenia, microangiopathic he‐molytic anemia, and a localized consumption coagulopathy that develops within the abnormal vascular channels of a hemangioma. In general, these patients demonstrate only mild abnormalities of screening clotting tests, but they can potentially develop life‐threatening complications. We present a patient who developed a severe anemia that was refractory to erythrocyte transfusions. Treatment with epsilon‐aminocaproic acid to inhibit fibrinolysis and cryoprecipitate to replenish his deficient circulating fibrinogen interrupted the cycle of his systemic coagulopathy and enabled us to transfuse him to a normal hematocrit.
Daily pattern of sweating and response to stress and exercise in patients with palmar hyperhidrosis
Authors: A.L. Krogstad, C. Mork, S.K. Piechnik
Journal: British Journal of Dermatology (2006)

Journal Article Daily pattern of sweating and response to stress and exercise in patients with palmar hyperhidrosis Get access A.L. Krogstad, A.L. Krogstad Department of Dermatology, Rikshospitalet University Hospital, 0027 Oslo, NorwayInstitute of Clinical Neuroscience, Göteborg University, Göteborg, SwedenDepartment of Dermatology, Sahlgren University Hospital, Göteborg, Sweden Anne‐Lene Krogstad. E‐mail: anne‐lene.krogstad@neuro.gu.se Search for other works by this author on: Oxford Academic Google Scholar C. Mork, C. Mork Department of Dermatology, Rikshospitalet University Hospital, 0027 Oslo, Norway Search for other works by this author on: Oxford Academic Google Scholar S.K. Piechnik S.K. Piechnik Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, Oxford University, Oxford, U.K Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 154, Issue 6, 1 June 2006, Pages 1118–1122, https://doi.org/10.1111/j.1365-2133.2006.07212.x Published: 01 June 2006 Article history Accepted: 28 November 2005 Published: 01 June 2006
Survival analysis of variceal hemorrhage: Does it matter when the meter is started?
Authors: J. Lacey Smith, David Y. Graham
Journal: Hepatology (1988)

Variation in time of patient admission to studies of prognosis after variceal hemorrhage has been proposed as a major factor in the wide range of reported results. A study of 144 unselected subjects with a low initial mortality (3% at two days) suggests that the effect has been overemphasized and studies in which time of entry is later than the date of bleeding may be usefully compared. Reanalysis of previous work suggests that even in populations with a high initial mortality limited comparisons between studies can still be usefully made. It is stressed that survival analysis must be started from the date of study entry and not from the date of the index bleed which involves incorporating a retrospective period of survivorship.
Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420
Authors: Alberto Broniscer, John C. Panetta, Melinda O'Shaughnessy, Charles Fraga, Feng Bai, Matthew J. Krasin, Amar Gajjar, Clinton F. Stewart
Journal: Clinical Cancer Research (2007)

Abstract Purpose: To report cerebrospinal fluid (CSF) penetration of erlotinib and its metabolite OSI-420. Experimental Design: Pharmacokinetic measurements were done in plasma (days 1, 2, 3, and 8 of therapy) and, concurrently, in plasma and CSF (before and at 1, 2, 4, 8, and 24 h after dose on day 34 of therapy) in an 8-year-old patient diagnosed with glioblastoma who received local irradiation and oral erlotinib in a phase I protocol. CSF samples were collected from a ventriculoperitoneal shunt, which was externalized because of infection. Erlotinib concentrations were determined by liquid chromatography/mass spectrometry. CSF penetration of erlotinib and OSI-420 were estimated by a compartmental model and by calculating the ratio of CSF to plasma 24-h area under concentration-time curve (AUC0-24). Results: This patient was assigned to receive erlotinib at a dose level of 70 mg/m2, but the actual daily dose was 75 mg (78 mg/m2). Erlotinib and OSI-420 plasma pharmacokinetic variables on days 8 and 34 overlapped to suggest that steady state had been reached. Whereas erlotinib and OSI-420 AUC0-24 in plasma on day 34 were 30,365 and 2,527 ng h/mL, respectively, the correspondent AUC0-24 in the CSF were 2,129 and 240 ng h/mL, respectively. Erlotinib and OSI-420 CSF penetration were 7% and ∼9%, respectively, using both estimate methods. The maximum steady-state CSF concentration of erlotinib was ∼130 ng/mL (325 nmol/L). Conclusions: The plasma pharmacokinetics of erlotinib in this child overlapped with results described in adults. Oral administration of erlotinib achieves CSF concentrations comparable with those active against several cancer cell lines in preclinical models.
An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis
Authors: Hideki Kizawa, Ikuyo Kou, Aritoshi Iida, Akihiro Sudo, Yoshinari Miyamoto, Akira Fukuda, Akihiko Mabuchi, Akihiro Kotani, Akira Kawakami, Seizo Yamamoto, Atsumasa Uchida, Kozo Nakamura, Kohei Notoya, Yusuke Nakamura, Shiro Ikegawa
Journal: Nature Genetics (2005)
ATP Assay: Ability To Distinguish Cytostatic From Cytocidal Anticancer Drug Effects&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Harinder S. Garewal, Frederick R. Ahmann, Ron B. Schifman, Abbie Celniker
Journal: JNCI Journal of the National Cancer Institute (1986)

A bioluminescence assay for ATP was adapted to human cancer cell lines and used to study the effect of anticancer drugs on malignant cell growth by following serial ATP measurements. Eleven drugs were tested against a colon cancer cell line (WiDR). Excellent correlation was observed between simultaneously performed soft-agar colony-forming assays and the ATP assay. In addition, cytostatic (growth inhibitory) drug effects could be distinguished from cytocidal (lethal) effects by using the ATP assay. Cytocidal drugs resulted in a reduction of ATP level below baseline levels, whereas cytostatic drugs merely yielded a reduction in the rate of increase in ATP level, i.e., slower growth. Such characterizations are not possible in colony-forming assays. Changes in ATP were correlated with the number of viable cells present. Drug concentration and duration of exposure both were important. Some drugs became cytocidal only when exposures longer than the customary 1 hour were used. The ATP assay has excellent potential as a simple, inexpensive, and rapid technique for new drug screening in cell lines, with classification of drug effects as cytostatic or cytocidal.
Quality of Life in Advanced Colorectal Cancer
Authors: Thierry Conroy, Francis Guillemin
Journal: Journal of Clinical Oncology (1999)

Colorectal carcinoma is a knowingly chemoresistant neoplasia. Fluorouracil (5-FU) is considered the standard drug for the treatment of advanced colorectal cancer and it is known that the action of 5-FU is potentiated by Folinic-acid (FA).
Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma
Authors: Erick Riquelme, Milind B. Suraokar, Jaime Rodriguez, Barbara Mino, Heather Y. Lin, David C. Rice, Anne Tsao, Ignacio I. Wistuba
Journal: Journal of Thoracic Oncology (2014)
A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer
Authors: Martee L. Hensley, Joseph Larkin, Matthew Fury, Scott Gerst, D. Fritz Tai, Paul Sabbatini, Jason Konner, Mauro Orlando, Tiana L. Goss, Carol A. Aghajanian
Journal: Clinical Cancer Research (2008)

Abstract Purpose: To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B12 and folate supplementation in patients with advanced solid tumors and ovarian cancer. Experimental Design: Patients with no prior pemetrexed or gemcitabine therapy enrolled in cohorts of three, expanding to six if dose-limiting toxicity (DLT) was observed. Pemetrexed, escalated from to 700 mg/m2, was given before gemcitabine 1,500 mg/m2 every 14 days. DLTs were grade 4 neutropenia lasting &amp;gt;7 days or febrile neutropenia, grade 4 or 3 thrombocytopenia (with bleeding), grade ≥3 nonhematologic toxicity, or treatment delay of ≥1 week due to unresolved toxicity. Results: The ovarian cancer cohort enrolled 24 patients with unlimited prior cytotoxic chemotherapies. MTD was observed at pemetrexed 600 mg/m2, with 2 of 9 patients experiencing DLT. Most common grade 3 to 4 toxicities per patient were neutropenia (83%), leukopenia (67%), lymphopenia (73%), and febrile neutropenia (12%). Median cycle per patient was 8 (range, 1-16). Six of 21 (28%) patients had confirmed partial responses. Study protocol was modified for the solid tumor cohort (n = 30) to enroll patients with two or more prior cytotoxic regimens. MTD was observed at pemetrexed 500 mg/m2, with 1 of 9 patients experiencing DLT. Most common grade 3 to 4 toxicities per patient were neutropenia (63%), lymphopenia (43%), leukopenia (70%) and febrile neutropenia (6.6%). Median cycle per patient was 4 (range, 1-20). Three of 29 (10.3%) response-evaluable patients had confirmed partial responses: 2 squamous cell carcinomas of head and neck and 1 nasopharyngeal cancer. Conclusion: MTDs for the solid tumor and ovarian cancer cohorts were reached at pemetrexed 500 and 600 mg/m2, respectively, given biweekly with gemcitabine 1,500 mg/m2.
Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection.
Authors: C Li, L S Fung, S Chung, A Crow, N Myers-Mason, M J Phillips, J L Leibowitz, E Cole, C A Ottaway, G Levy
Journal: The Journal of Experimental Medicine (1992)

The induction of monocyte/macrophage procoagulant activity (PCA) has been implicated in the pathogenesis of murine hepatitis virus strain 3 (MHV-3) infection and disease. Previously, we have shown that induction of PCA by MHV-3 correlated with resistance/susceptibility to infection in different mouse strains. In this study, all BALB/cJ mice that were infected with 10(3) plaque-forming units of MHV-3 developed severe liver disease and died within 96-120 h. Examination of the livers of these animals showed marked hepatic necrosis, deposition of fibrin, and cellular expression of PCA by direct immunofluorescence staining in areas of necrosis as well as in hepatic sinusoids. Splenic mononuclear cells recovered from these mice expressed high concentrations of PCA with time after infection. Infusion into mice of a high-titered monoclonal antibody that neutralized PCA (3D4.3) attenuated the development of hepatic necrosis and enhanced survival in a dose-dependent manner. All of the animals receiving 100 micrograms, and 44% and 22% of the animals that received 50 and 25 micrograms per day, respectively, survived for 10 d and made a full recovery. Administration of the antibody resulted in a dose-dependent reduction in fibrin deposition, PCA expression as detected by direct immunofluorescence staining and by a functional assay. In animals treated with high concentrations of antibody, titers of antibody to PCA fell from 87 +/- 15 micrograms/ml to 100 +/- 7 ng/ml during the active phase of the disease, consistent with sequestration due to binding of the immunoglobulin to cells expressing PCA. Surviving animals, when rechallenged with MHV-3, had a 40% mortality, consistent with the known rates of metabolism of immunoglobulin. This further suggested that protection was by a passive mechanism. The results reported here demonstrate that a neutralizing antibody to PCA protects animals from fulminant hepatitis and death associated with MHV-3 infection, and supports the notion that PCA is a potent inflammatory mediator that plays a pivotal role in the pathogenesis of liver injury resulting from MHV-3 infection.
Pulmonary hypertension in patients with COPD: NO treatment?
Authors: J Pepke-Zaba
Journal: Thorax (2003)

The application of “pulsed” NO combined with LTOT may have a role in treating pulmonary hypertension secondary to COPD.

Following the identification of nitric oxide (NO) in 1986 as “endothelium derived relaxing factor”, there has been an exponential growth in our understanding of the physiological role of NO culminating in the award of a Nobel Prize, and the naming of NO as “molecule of the decade”.1 Considerable research has subsequently been devoted to understanding the role of this molecule in vascular biology in general, and the pulmonary vascular system in particular.

NO is an unstable radical with a low blood gas partition coefficient. For decades NO was considered an environmental contaminant produced by bacteria and internal combustion engines. Believed to be highly toxic, it appeared an unlikely candidate for a major role as a biological mediator. However, within the last 15 years it has become clear that endogenously produced NO is ubiquitous in mammalian systems, playing an important role in both health and disease: in the regulation of blood pressure and flow, inflammatory responses, and neurotransmission. Insight into these physiological roles has led to its use as a therapeutic agent in a number of clinical settings.

There are ample data to support a major role for NO in the regulation of tone and vascular remodelling in the normal and diseased pulmonary circulation. Endothelial NO contributes significantly to the normally low …
Loss of Strain Specificity of the TA3-St Subline: Evidence for the Role of Epiglycanin in Mouse Allogeneic Tumor Growth&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: A G Cooper, J F Codington, D K Miller, M C Brown
Journal: JNCI Journal of the National Cancer Institute (1979)

We described the in vivo conversion of the strain-specific ascites murine mammary adenocarcinoma subllne TA3-St to a new ascites subline designated TA3-MM. This conversion occurred during passage in a syngeneic A/HeHa mouse infected with pneumonia-producing microorganisms. The mode number of chromosomes of the TA3-MM cell (82) was greater than that of the parental TA3-St cell (69) or the other non-strain-specific subline TA3-Ha (42). The TA3-MM subllne could grow in and kill mice of various allogeneic strains. In addition, the TA3-MM cell possessed numerous receptors for the lectin of Vicia graminea seeds, which were hardly detectable at the surface of the parent TA3-St subline but were present in abundance at the cell surface of the non-strain-specific subline TA3-Ha. These lectin receptors of the TA3-Ha cell were previously demonstrated to be present in a unique high-molecular-weight endogenous cell surface glycoprotein termed eplglycanin. The V. graminea lectin receptors on the new TA3-MM subline also were present on an epiglycanin-like molecule. This finding provides further evidence for the hypothesis that allogeneic growth in the TA3 system is a direct result of these membrane glycoproteins.
Gene Expression Signatures Diagnose Influenza and Other Symptomatic Respiratory Viral Infections in Humans
Authors: Aimee K. Zaas, Minhua Chen, Jay Varkey, Timothy Veldman, Alfred O. Hero, Joseph Lucas, Yongsheng Huang, Ronald Turner, Anthony Gilbert, Robert Lambkin-Williams, N. Christine Øien, Bradly Nicholson, Stephen Kingsmore, Lawrence Carin, Christopher W. Woods, Geoffrey S. Ginsburg
Journal: Cell Host & Microbe (2009)
Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD
Authors: M M Peters
Journal: Thorax (2006)

<b>Background:</b> Studies examining the physiological interactions of oxygen (O<sub>2</sub>) and bronchodilators (BD) during exercise in chronic obstructive pulmonary disease (COPD) should provide new insights into mechanisms of exercise intolerance. We examined the effects of O<sub>2</sub> and BD, alone and in combination, on dyspnoea, ventilation (V̇e), breathing pattern, operating lung volumes, and exercise endurance. <b>Methods:</b> In a randomised, double blind, crossover study, 16 patients with COPD (mean (SE) FEV<sub>1</sub> 43(3)% predicted) performed pulmonary function tests and an incremental exercise test, then completed four visits in which they received either nebulised BD (ipratropium 0.5 mg + salbutamol 2.5 mg) or placebo (PL) with either 50% O<sub>2</sub> or room air (RA). After 90–105 minutes the patients performed pulmonary function tests, then breathed RA or O<sub>2</sub> during symptom limited constant load exercise at 75% peak work rate. <b>Results:</b> With BD the mean (SE) increase in inspiratory capacity (IC) was 0.3 (0.1) l (p&lt;0.05) at rest and during exercise, permitting greater tidal volume (Vt) expansion during exercise and a greater peak V̇e. With O<sub>2</sub>, V̇e decreased during exercise as a result of decreased breathing frequency (<i>F</i>), with no significant change in IC. During exercise with BD+O<sub>2</sub>, IC and Vt increased, <i>F</i> decreased, and V̇e did not change. Dyspnoea decreased with all interventions at a standardised time during exercise compared with PL+RA (p&lt;0.05). Endurance time was significantly (p&lt;0.05) greater with BD+O<sub>2</sub> (10.4 (1.6) min) than with O<sub>2</sub> (8.5 (1.4) min), BD (7.1 (1.3) min) and PL+RA (5.4 (0.9) min). <b>Conclusion:</b> By combining the benefits of BD (reduced hyperinflation) and O<sub>2</sub> (reduced ventilatory drive), additive effects on exercise endurance were observed in patients with normoxic COPD.
The Canadian C-Spine Rule versus the NEXUS Low-Risk Criteria in Patients with Trauma
Authors: Ian G. Stiell, Catherine M. Clement, R. Douglas McKnight, Robert Brison, Michael J. Schull, Brian H. Rowe, James R. Worthington, Mary A. Eisenhauer, Daniel Cass, Gary Greenberg, Iain MacPhail, Jonathan Dreyer, Jacques S. Lee, Glen Bandiera, Mark Reardon, Brian Holroyd, Howard Lesiuk, George A. Wells
Journal: New England Journal of Medicine (2003)

The Canadian C-Spine (cervical-spine) Rule (CCR) and the National Emergency X-Radiography Utilization Study (NEXUS) Low-Risk Criteria (NLC) are decision rules to guide the use of cervical-spine radiography in patients with trauma. It is unclear how the two decision rules compare in terms of clinical performance.
A novel hypomorphic mutation in STIM1 results in a late-onset immunodeficiency
Authors: Heidi Schaballie, Rémy Rodriguez, Emmanuel Martin, Leen Moens, Glynis Frans, Christelle Lenoir, Joris Dutré, Danielle Canioni, Xavier Bossuyt, Alain Fischer, Sylvain Latour, Isabelle Meyts, Capucine Picard
Journal: Journal of Allergy and Clinical Immunology (2015)
Physicochemical and bacteriological analysis of the contents of occluded biliary endoprostheses
Authors: Christian Moesch, Denis Sautereau, Franclois Cessot, Pascal Berry, Marcelle Mounier, Alain Gainant, Bernard Pillegand
Journal: Hepatology (1991)

The deposits obstructing 12 biliary endoprostheses were examined by scanning electron microscopy and analyzed quantitatively by Fourier transform infrared spectroscopy. Calcium palmitate and bilirubinate associated with proteins were found in all the deposits. Apart from the small amount of cholesterol, this composition closely resembled that of brown pigment gallstones and suggested an infectious cause. Facultative aero-anaerobic organisms were found on bacteriological investigation. beta-Glucuronidase activity was only detected in one sample, suggesting that the calcium bilirubinate may have been formed through tissue glucuronidases. In our study, deposit formation was thought to have been caused by the action of bacterial phospholipases (although not measured) rather than beta-glucuronidases.
Our Time: A Call to Save Preventable Death From Cardiovascular Disease (Heart Disease and Stroke)
Authors: Sidney C. Smith, Amy Collins, Roberto Ferrari, David R. Holmes, Susanne Logstrup, Diana Vaca McGhie, Johanna Ralston, Ralph L. Sacco, Hans Stam, Kathryn Taubert, David A. Wood, William A. Zoghbi
Journal: Circulation (2012)
Change in Character of Mitral Prosthesis Regurgitant Murmur With Bundle-Branch Block
Authors: Elizabeth W. Ryan, Elyse Foster
Journal: Circulation (2001)

old woman, in whom a Carpentier Edwards porcine mitral valve prosthesis (No. 29) had been implanted in 1990, presented with episodic breathlessness and dizziness.Examination revealed an apical pansystolic murmur with a frequent but intermittent loud musical "honking" character.The patient was in sinus rhythm, 68 to 74 bpm, with alternating runs of narrow QRS and bundle-branch block.The amplified, honking quality was observed intermittently only during periods of narrow QRS complexes.Echocardiography revealed thickened prosthesis leaflets, a 3-mm vibrating density (Figure 1) on the leaflet's atrial surface, and a 2-mm systolic coaptation defect with
Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme
Authors: Haseem Ashraf, Zaigham Saghir, Asger Dirksen, Jesper Holst Pedersen, Laura Hohwü Thomsen, Martin Døssing, Philip Tønnesen
Journal: Thorax (2014)

<h3>Background</h3> We present the final results of the effect of lung cancer screening with low-dose CT on the smoking habits of participants in a 5-year screening trial. <h3>Methods</h3> The Danish Lung Cancer Screening Trial (DLCST) was a 5-year screening trial that enrolled 4104 subjects; 2052 were randomised to annual low-dose CT (CT group) and 2052 received no intervention (control group). Participants were current and ex-smokers (≥4 weeks abstinence from smoking) with a tobacco consumption of ≥20 pack years. Smoking habits were determined annually. Missing values for smoking status at the final screening round were handled using two different models. <h3>Results</h3> There were no statistically significant differences in annual smoking status between the CT group and control group. Overall the ex-smoker rates (CT + control group) significantly increased from 24% (baseline) to 37% at year 5 of screening (p&lt;0.001). The annual point prevalence quit rate increased from 11% to 24% during the five screening rounds; the ex-smokers' relapse rate remained stable, around 11%, across the same period. <h3>Conclusions</h3> Screening with low-dose CT had no extra effect on smoking status compared with the control group, but overall the screening programme probably promoted smoking cessation. <h3>Clinical Trial Registration:</h3> The DLCST is registered in Clinical Trials.gov Protocol Registration System (identification no. NCT00496977).